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Abstract
Background: Cachexia is a common problem in patients (pts) suffering from upper gastrointestinal cancer. In
addition, most of these patients suffer from malabsorption and stenosis of the gastrointestinal tract due to their
illness. Various methods of supplementary nutrition (enteral, parenteral) are practised. In patients with advanced
pancreatic cancer (APC), phase angle, determined by bio-electrical impedance analysis (BIA), seems to be a survival
predictor. The positive influence of BIA determinate predictors by additional nutrition is currently under discussion.
Methods: To examine the impact of additional parenteral nutrition (APN) we assessed outpatients suffering from
APC and progressive cachexia. The assessment based on the BIA method. Assessment parameters were phase
angle, ECM/BCM index (ratio of extracellular mass to body cell mass), and BMI (body mass index). Patients suffering
from progressive weight loss in spite of additional enteral nutritional support were eligible for the study.
Results: Median treatment duration in 32 pts was 18 [8-35] weeks. Response evaluation showed a benefit in 27 pts
(84%) in at least one parameter. 14 pts (43.7%) improved or stabilised in all three parameters. The median ECM/
BCM index was 1.7 [1.11-3.14] at start of APN and improved down to 1.5 [1.12-3.36] during therapy. The median
BMI increased from 19.7 [14.4-25.9] to 20.5 [15.4-25.0]. The median phase angle improved by 10% from 3.6 [2.3-5.1]
to 3.9 [2.2-5.1].
Conclusions: We demonstrated the positive impact of APN on the assessed parameters, first of all the phase
angle, and we observed at least a temporary benefit or stabilisation of the nutritional status in the majority of the
investigated patients. Based on these findings we are currently investigating the impact of APN on survival in a
larger patient cohort.
Trial registration: ClinicalTrials.gov Identifier: NCT00919659
Background
Pancreatic adenocarcinoma is a highly aggressive cancer
type being nearly chemoresistant, characterised by early
local spread, extensive invasion and precocious metasta-
sis. It is associated with marked cachexia. In spite of
intensive experimental research in the last decade, the
five year survival rate is still less than 5% [1,2]. Besides
rapid disease progression, patients suffer from merged
collateral symptoms including abdominal pain, nausea,
emesis, inability for natural nutrition intake, taste
abnormalities, early satiety, fatigue, stenosis, malabsorp-
tion and maldigestion. These additional symptoms con-
tribute substantially to degradation in the performance
status and quality of life [3-5]. The combination of these
symptoms, usually called “cancer anorexia-cachexia syn-
drome”, is considered an independent predictor of mor-
tality and poor therapeutic response [6]. Nearly 50% of
the patients with gastrointestinal malignancies suffer
from this debilitating disease, whose most important
phenotypic feature is muscle wasting and functional
impairment caused by protein degradation combined
with reduced protein synthesis [7]. Patients affected with
advanced pancreatic cancer have the highest incidence
of cancer cachexia, amounting to nearly 80 per cent of
pts. at the time of diagnosis [6]. Nutritional support has
often been practised in comprehensive cancer therapy.
Various configurations of support have been used to
improve or stabilise patient performance status, prog-
nosis and response to therapy and also to reduce the
complications of treatment.
* Correspondence: uwe.pelzer@charite.de
1Universitätsmedizin Berlin, Charité Centrum für Tumormedizin, CONKO -
Study Group, Augustenburger Platz 1, Berlin, Germany
Pelzer et al. BMC Cancer 2010, 10:86
http://www.biomedcentral.com/1471-2407/10/86
© 2010 Pelzer et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
Common evaluation parameters of the nutritional sta-
tus (e.g. weight change, mid arm muscle circumference,
triceps skin fold thickness) or laboratory measurements
are unstable in the clinical setting of cancer patients.
Some of the serum parameters (e.g. serum albumin,
transferrin) are likely to be influenced by many non
nutritional factors [8]. A more objective assessment is
provided by the BIA method. BIA measurements and
particularly the parameter phase angle, have been pro-
ven suitable for evaluating the nutritional status in APC
patients. Phase angle estimation may be used for survi-
val prediction [9].
The method is based on the electrical characteristics of
the human body. The key characteristic is the almost
complete conduction of a fixed, low voltage, high fre-
quency alternating current through the fluid compart-
ment of the fat-free mass in the human body [10]. The
body component resistance (R) and capacitance (Xc) are
measured by estimating a voltage discrepancy in the
applied current. The resistive effect (Xc) at tissue inter-
faces and cell membranes generates a phase shift. The
shift is quantified geometrically as the angular transfor-
mation of the capacitance to resistance ratio, referred to
as phase angle [11]. Phase angle reflects the relative con-
tributions of fluid (R) and cellular membranes (Xc) and is
positively associated with capacitance and negatively with
resistance [11]. It characterises the distribution of water
between the extracellular and the intracellular spaces,
which is one of the most sensitive indicators of malnutri-
tion [12]. The ECM/BCM index describes the nutritional
status in a similar way [13]. BCM is the whole cell mass
responsible for metabolism; ECM includes the connective
tissues such as collagen, elastin, skin, chords, bones as
well as interstitial water (ascites, pleural effusion etc.). In
healthy individuals, the BCM is always distinctly higher
than the ECM, so the index is < 1 [13]. A rising ECM/
BCM index is an early warning sign of a worsening nutri-
tional status. However, the index is also influenced by
over-hydration or dehydration of the body.
In the current study, we investigated the impact of
additional parenteral nutrition on the nutritional status
in APC patients by using BIA parameters like phase
angle, ECM/BCM index and BMI.
Methods
Ambulant patients with stage IV inoperable pancreatic
cancer and reduced nutritional status were evaluated
between January 2002 and January 2004 (Table 1). All
patients gave their informed consent to the evaluation,
the trial was conducted in compliance with the Helsinki
Declaration, was approved by the local ethics committee
and registered in accordance with the International
Committee of Medical Journal Editors (NCT00919659).
First a dietician assessed the baseline nutritional status
in all patients. The clinical check up was arranged by
the supervising physician. Candidates for APN were
patients with weight losses over 5% in the previous four
weeks or BMI below 19 in spite of additional enteral
caloric support (carbohydrate suspensions 200-400 ml,
1.5 kcal/ml) combined with drug support (antiemetic,
corticosteroid, prokinetics, gestagen, cannabinoids).
Almost all patients suffered from gastrointestinal steno-
sis, gastro-paresis and loss of appetite. The potential
changes in the nutritional status during our intervention
were assessed by BIA. The BIA measurements were per-
formed according to the common operating manual
guidelines exemplified in the paperwork by Gupta et al.
[9]. The fundamental design parameters were as follows:
patients in horizontal supine position on an examination
table, extremities apart and not touching each other or
the torso; the four surface standard electrode (tetrapo-
lar) technique was used in such a way that two electro-
des were placed on the right hand and the remaining
two electrodes on the right leg. Resistance, capacitance
and phase angle were directly measured (optimal cali-
bration at 50 kHz, 800 μA). ECM, BCM and BMI were
calculated. Statistic calculations were done by using
SPSS 11.5 (SPSS Inc., Chicago, IL, USA).
APN was arranged on an overnight home treatment
basis and consisted of caloric intake of about 25 kcal/kg
daily on five out of seven days (amino-acids 1.2 to 1.5 g/
kg, lipids at least 35% of the whole energy support, addi-
tional vitamins or electrolyte if indicated, no additional
glutamine or ω-3 fatty acid). Patient height and body
weight were measured using a calibrated scale to calcu-
late the individual BMI. Response was evaluated
according to Table 2.
Table 1 Patient characteristics at start of APN
Character Range
Screened patients 65
Recruited patients 32
Female 14
Male 18
Age 62 years [47-75]
Histology pancreatic adenocarcinoma
Metastatic disease 32
Median BMI 19.7 kg/m2 [14.4 to 25.0]
Median Phase angle 3.6° [2.3 to 5.1]
Median ECM/BCM index 1.7 [1.1 to 3.1]
Table 2 Nutritional status - study assessment rules
Parameter Improvement Stabilisation Impairment
BMI > + 5% +/- 5% > - 5%
ECM/BCM index > - 5% +/- 5% > + 5%
Phase angle > + 5% +/- 5% > - 5%
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Results
Sixty five ambulant pts with histologically proven APC
had been screened between January 2002 and January
2004 in our university outpatient clinic in Berlin/Ger-
many. 32 of them suffered from marked progressive
cachexia and were willing to receive APN. Median treat-
ment duration was 18 (8-35) weeks. The nutritional sta-
tus was evaluated by BIA every 4 to 6 (2-8) weeks. Figure
1 represents the median response. The median BMI at
start of APN was 19.7 (14.4-25.9) and increased to 20.5
(15.4-25.0) during APN therapy. The median ECM/BCM
index at start of APN was 1.7 (1.11-3.14) and decreased
to 1.5 (1.12-3.36). The main parameter, phase angle,
increased by 10%, from 3.6 (2.3-5.1) to 3.9 (2.2-5.1).
Nearly half the patients (15/32) had a temporarily
improved phase angle, and in 13/32 pts. we observed a
stabilisation of this parameter. Only 13% (4/32) of pts.
showed a decrease in phase angle in spite of APN.
Figure 2 typifies the specific response. Improvement in
at least one parameter was seen in 27 of the 32 pts
(84%). In 15 pts.(46%) we observed an improvement in
two main parameters of nutritional performance. 9 pts.
(28%) improved in all three parameters (BMI, phase
angle, ECM/BCM index). 12 pts. (38%) stabilised in two
of the main parameters, 5 pts. (16%) in all three para-
meters. In 5 pts (16%) APN was without any positive
effect, 3 of them did even degrade in all three para-
meters while receiving APN. By longer treatment,
beyond the achieved response, we do not obtain higher
response. All patients were still alive at the end of the
intervention. No severe side effects (e.g. over-hydration,
electrolyte disturbances, venous port infection) were
observed.
Discussion
Only few data are available to shed light on the prog-
nostic impact of phase angle on overall survival in pan-
creatic cancer [9]. The goal of our study was phase
angle improvement via APN. The majority of the
patients supported by APN showed an improved nutri-
tional status, which was verified by changes in the target
parameters.
Phase angle improved from 3.6 to 3.9, the ECM/BCM
index dropped from 1.7 down to 1.5, and the BMI
increased slightly from 19.7 to 20.5. However, overall
normalisation of the BIA parameters was not achieved
by APN.
Our study design did not allow us to draw conclusions
as to the clinical relevance (eg.: overall survival, quality
of life) of the findings. A randomised study design with
a control group (no APN support) would probably have
yielded more powerful data. But for ethical concerns,
conduction of such a study is absolutely out of the
question.
Nevertheless we demonstrated the positive effect of
the study intervention on the nutritional status of the
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Figure 1 Median best response of study cohort in terms of BMI, ECM/BCM index and phase angle.
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patients. The pre-existing data support the direct corre-
lation between overall survival and phase angle in
patients with APC [9]. Beside BMI or specific weight
loss, the ECM/BCM index proved to be a useful tool for
nutritional assessment. A decreasing ECM/BCM index
resulted in a recovery in patients with malnutrition due
to gastrointestinal non-malignant diseases [14].
If baseline and changes in the nutritional status are
determined by BIA parameters alone, limitations of the
BIA technique should be taken into account. A poten-
tial limitation is its reliance on regression models that
are derived from a limited number of human subjects.
These models fail to work properly in patients who are
different from the original patient sample [15,16]. Varia-
bility in the direct bio-impedance measures (resistance,
capacitance and phase angle) is likely due to age, gen-
der, and body mass characteristics of the study
population.
Other reported limitations are hydration status and
major disturbances of water distribution, body position
during the procedure, ambient air and skin tempera-
tures, recent physical activity, conductance of the exam-
ining table, and food consumption [15,17]. Not all of
these factors could be controlled in this trial. Yet signs
of over-hydration were under control and all our
patients were found free from visible oedema or ascites.
Body position was controlled at examination, extreme
physical activity was anyway most unlikely in these
patients. Air temperature was within the controlled
range in the outpatient department.
Difficulties in the process of analysis were caused by
the individually tailored chemotherapy, supportive
drugs, patient opinion, course of disease and compli-
cated assessment of remaining enteral nutrition. Due to
the small size of the study we were not able to exclude
these influencing variables or arrange them in sub-
groups. Patients were treated with APN until they or
their physicians did not see any further benefit from it.
Conclusions
In summary, our present study has demonstrated the
positive impact of APN on the nutritional status of
patients with APC. Proceeding from these results we
have started the next study phase with a larger patient
cohort to correlate the level of nutritional improvement
with overall survival and quality of life.
The decision if APN was indicated or not was taken in
accordance with the current ESPEN (European Society
for Clinical Nutrition and Metabolism) guidelines, which
are congruent with our appraisal [18]. Home parenteral
nutrition may be recommended for hypophagic/(sub)
obstructed cancer patients with acceptable performance
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Figure 2 Number of individual responders in terms of BMI, ECM/BCM index or phase angle.
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status if they are expected to die from starvation prior
to cancer spread.
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